Project

aignostics

aignostics Logo
Keywords

aignostics pioneers AI-based precision diagnostics for pharmaceutical research, clinical trials, and more.

Spin-Off

Project Website

Histological image analysis, performed by pathologists, is a crucial step in diagnosing many autoimmune, degenerative and infectious diseases. Given our aging population and the increase of cancer cases worldwide, a global shortage of pathologists is expected. To address this challenge, team aignostics has developed a patented “Explainable AI” (layer-wise relevance propagation) to assist pathologists in standardized and automated qualification and quantification of tissue features.

Frederick Klauschen
Frederick Klauschen
(Charité)

Project Lead

This solution is more accurate and faster than today’s manual gold standard. The system can also be applied to drug development. Pharmaceutical companies can augment histomorphological assessments in preclinical animal studies or in clinical trials to stratify patients in order to further improve drug efficacy and toxicity analyses. Prof. Federick Klauschen, Viktor Matyas, Dr. Maximilian Alber founded in cooperation with Prof. Klaus-Robert Müller, a globally renowned expert on machine learning from Technical University Berlin, aignostics in 2020.

The Berlin-based company is funded by Boehringer Ventures and HTGF and has over 40 employees with interdisciplinary expertise to date.

DHA

Project Lead

Frederick Klauschen

aignostics (Spin-Off)

„The DHA program delivered an outstanding support on our way to a solid transition from research to market with expertise, endurance and connections. For years, we have talked about building an Al-powered precision diagnostic pathology solution for drug development and clinical routine. Without the BIH DHA program, we would still be talking today.“

Frederick Klauschen

(Charité)